Kiss A, Wang N J, Xie J P, Thorgeirsson S S
Laboratory of Experimental Carcinogenesis, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
Clin Cancer Res. 1997 Jul;3(7):1059-66.
Experimental data suggest that dysregulation of growth factors and the cognate receptors may play an important role in hepatocarcinogenesis. The objective of the present study was to characterize the expression of two hepatotrophic growth factor/receptor systems [transforming growth factor-alpha/epidermal growth factor receptor (TGF-alpha/EGFR) and hepatocyte growth factor/c-met receptor (HGF/c-met)], both of which are implicated in the development of human liver tumors. In addition, we have analyzed the expression of transforming growth factor-beta receptor type II (TGF-beta-RII) and p53, genes associated with growth inhibition and tumor suppression, respectively. Surgical biopsy specimens from 86 human hepatocellular carcinomas were analyzed. TGF-alpha was overexpressed in 17%, equally expressed in 21%, and down-regulated in 62% of the hepatocellular carcinomas when compared to the surrounding hepatic tissue. No major changes were found with EGFR expression. HGF was over-expressed in 33% and down-regulated in 21% of the tumors. The c-met receptor was overexpressed in 20%, equally expressed in 48%, and down-regulated in 32% of the neoplasms. In contrast, TGF-beta-RII was overexpressed in only 8%, equal in 42%, and down-regulated in 50% of tumors. Nuclear staining of p53, indicative of a mutation(s), was observed in the great majority of the tumors (80%), whereas no nuclear p53 was detected in peritumoral tissues. Interestingly, simultaneous down-regulation of c-met and TGF-beta-RII was observed in 23% of the hepatocellular carcinomas, 85% of which also showed nuclear p53 staining. Taken together, our data suggest that down-regulation of c-met and TGF-beta-RII may, together with p53 mutations, play a significant role in human liver carcinogenesis.
实验数据表明,生长因子及其相关受体的失调可能在肝癌发生过程中起重要作用。本研究的目的是描述两种肝营养生长因子/受体系统[转化生长因子-α/表皮生长因子受体(TGF-α/EGFR)和肝细胞生长因子/c-met受体(HGF/c-met)]的表达情况,这两种系统均与人类肝脏肿瘤的发生有关。此外,我们还分析了分别与生长抑制和肿瘤抑制相关的转化生长因子-βⅡ型受体(TGF-β-RII)和p53的表达。对86例人类肝细胞癌的手术活检标本进行了分析。与周围肝组织相比,17%的肝细胞癌中TGF-α过表达,21%的肝细胞癌中TGF-α表达相当,62%的肝细胞癌中TGF-α表达下调。EGFR表达未发现重大变化。33%的肿瘤中HGF过表达,21%的肿瘤中HGF表达下调。20%的肿瘤中c-met受体过表达,48%的肿瘤中c-met受体表达相当,32%的肿瘤中c-met受体表达下调。相比之下,仅8%的肿瘤中TGF-β-RII过表达,42%的肿瘤中TGF-β-RII表达相当,50%的肿瘤中TGF-β-RII表达下调。在绝大多数肿瘤(80%)中观察到p53的核染色,提示存在突变,而在肿瘤周围组织中未检测到核p53。有趣的是,23%的肝细胞癌中观察到c-met和TGF-β-RII同时下调,其中85%的肝细胞癌也显示核p53染色。综上所述,我们的数据表明,c-met和TGF-β-RII的下调可能与p53突变一起在人类肝癌发生中起重要作用。